Tauroursodeoxycholic acid: relieving the pathogenesis of HFE C282Y hereditary hemochromatosis

Hepatology. 2008 Jul;48(1):344-5. doi: 10.1002/hep.22155.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antioxidants / therapeutic use*
  • Cysteine
  • Endoplasmic Reticulum / metabolism
  • Hemochromatosis / drug therapy*
  • Hemochromatosis / genetics*
  • Hemochromatosis / metabolism
  • Hemochromatosis Protein
  • Histocompatibility Antigens Class I / genetics*
  • Homozygote
  • Humans
  • Membrane Proteins / genetics*
  • Mutation
  • Reactive Oxygen Species / metabolism
  • Taurochenodeoxycholic Acid / therapeutic use*
  • Tyrosine

Substances

  • Antioxidants
  • HFE protein, human
  • Hemochromatosis Protein
  • Histocompatibility Antigens Class I
  • Membrane Proteins
  • Reactive Oxygen Species
  • Tyrosine
  • Taurochenodeoxycholic Acid
  • ursodoxicoltaurine
  • Cysteine